Modern chemotherapeutic options for malaria.
Unlike HIV disease or tuberculosis, both of which are also major threats to public health throughout the tropics, uncomplicated malaria of whatever species can be cheaply and rapidly cured, usually in outpatients. However, in common with both HIV and tuberculosis, control of malaria is threatened by inadequate resources and by drug resistance. Africa carries the greatest burden of malaria mortality and morbidity; by no coincidence, Africa is also the most resource-limited. The drugs for severe disease (quinine and the artemisinins) are largely unaffected by resistance so far, but the "first-line" drugs, mainly used by outpatients (eg, chloroquine and sulfadoxine-pyrimethamine), are a major cause for concern. Although effective drugs are available they are mostly too expensive for routine use. This article reviews the main drugs for malaria and outlines the therapeutic use of these drugs for uncomplicated and severe disease. The article then examines the challenges faced in the processes of changing policy, and the implementation of that policy shift.
Winstanley
P
P
Department of Pharmacology and Therapeutics, and Wellcome Trust Centre for Research in Clinical Tropical Medicine, University of Liverpool, UK. peterwin@liv.ac.uk
D000349:Africa / Q000453:epidemiology; D000818:Animals; D000962:Antimalarials / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D003906:Developing Countries / Q000191:economics; D004351:Drug Resistance; D006291:Health Policy; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D010963:Plasmodium falciparum / Q000187:drug effects*; D011634:Public Health
D000962:Antimalarials